A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
← catalyst calendarNCT07195682 · readout in 1,353 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
281estimated
Sites
11
Countries
Canada, France, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-15 | actual | When the study began enrolling |
| Primary completion | 2030-05-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-04-03 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Cell Carcinoma
Interventions
- Drug: BMS-986506
- Drug: Pumitamig — also filed as BMS-986545, BNT327, PM8002
- Drug: Ipilimumab — also filed as Yervoy, BMS-734016
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AEs)
measured Up to approximately 2 years from first dose of BMS-986506
Number of Participants With Serious Adverse Events (SAEs)
measured Up to approximately 2 years from first dose of BMS-986506
Number of Participants With AEs Meeting Protocol Defined Dose-limiting Toxicity (DLT) Criteria
measured Up to approximately Day 28
Number of Participants With AEs Leading to Discontinuation
measured Up to approximately 2 years from first dose of BMS-986506
Number of Participants With AEs Leading to Deaths as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0
measured Up to approximately 2 years from first dose of BMS-986506
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed